Real‐world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus
In a real-world population of US patients with T2DM, tirzepatide was associated with clinically and statistically significant reductions in A1C and body weight. Greater reductions in both A1C and body weight were observed among patients who were GLP1-RA naïve compared to patients switched from GLP1-RA to tirzepatide.
Authors
- Michael S. Kelly (ORCID: https://orcid.org/0000-0003-4272-8721)
- Barbara Simon (ORCID: https://orcid.org/0000-0002-3454-0166)
- Emily M. Scopelliti (ORCID: https://orcid.org/0000-0001-6985-6470)
- Kaylee E. Goodson
- Ching Mann Anne Lo
- Huelena X. Nguyen
Institutions
- Thomas Jefferson University (US)
- Jefferson College (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1111/dom.15934
- Citations
- 11
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.93